يعرض 1,041 - 1,060 نتائج من 13,275 نتيجة بحث عن '(( significantly ((teer decrease) OR (greater decrease)) ) OR ( significantly increased decrease ))', وقت الاستعلام: 0.54s تنقيح النتائج
  1. 1041
  2. 1042
  3. 1043
  4. 1044
  5. 1045
  6. 1046
  7. 1047
  8. 1048
  9. 1049
  10. 1050
  11. 1051
  12. 1052
  13. 1053
  14. 1054
  15. 1055
  16. 1056
  17. 1057

    Decreased childhood asthma hospitalizations linked to hotter, drier climate with lower wind speed in drylands حسب Klézio Silva Monte (20579829)

    منشور في 2025
    "…A generalized additive model analyzed the association between these trends, and the Mann-Kendall test determined if trends were increasing, decreasing, or not significant. Thirteen municipalities showed a significant link between hospitalizations and climate variables, especially wind speed, maximum temperature, and humidity. …"
  18. 1058

    Summary of study eligibility criteria. حسب Biban Gill (1473337)

    منشور في 2025
    "…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …"
  19. 1059

    Summary of study participation and feasibility. حسب Biban Gill (1473337)

    منشور في 2025
    "…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …"
  20. 1060

    TBSS results showing significant AxD and RD changes at baseline and the follow-up. حسب Sewon Lim (21989785)

    منشور في 2025
    "…<p>The regions indicated in green represent the mean white matter skeleton, whereas the regions indicated in red represent the regions with increased AxD (first row) and RD (second row). The decreased diffusivity metrics (AxD and RD) exhibited no statistically significant differences at <i><i>P</i></i> < 0.05 after correcting for multiple comparisons (FWE). …"